Unicorns 85/229 – BenevolentAI
Founder / s: Ivan Griffin, Ken Mulvany, Brent Gutekunst, Michael Brennan
Key people: Jerome Pesenti (CEO BenevolentTech), Michael Brennan (Co Founder – Head of Corporate Development), Ivan Griffin (Co Founder – VP Business Development), Brent Gutekunst (Co Founder – VP Technology Development) and Dewet Diener (VP Engineering)
Number of employees: 51 – 100
BenevolentAI was founded in 2013 (formerly as Stratified Medical) by the management team of Proximagen who have a track record of building is successful and disruptive technology companies. They saw the opportunity to for aa pair between technology and bioscience using AI in order to expand biomedical Discoveries
Quans; there are many four rounds of funding, raising a total of £ 87.72 million (circa $ 100m) at a final valuation of $ 1.781 billion. Lead prospects includ ed Woodford Investment Management, Lansdowne Partners, Lundbeck H / S And Upsher Smith Laboratories Inc.
In 2014 benevolent.ai signed a license deal with a US pharmaceutical organisation based on two novel targets for the treatment of Alzheimer’s disease.
In September 2016, the company changed its name from Stratified Medical to benevolent.ai to better reflect the wider application of its technology outside of human healthcare and drug discovery.